Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TX › Houston › NPI 1699172866
Lab OIG excluded

Landmark Diagnostics, LLC

Landmark Diagnostics, LLC was paid $119K by Medicaid between Jan 2018 and Aug 2019, across 25 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 25% of everything it billed.

33Billing provider infoLANDMARK DIAGNOSTICS, LLC
HOUSTON, TX 77054
33aNPI1699172866assigned 12/03/2014
28Total paid$119K
24GClaims5,531
24DCodes billed25
24AFirst – last monthJan 2018 – Aug 2019
Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#140 of 436
Median peer was paid$17K
This provider vs. median6.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

OIG exclusionListed on the federal exclusion list (05/07/2024).
Box 24A · Dates of service

Paid by month

$0$25K$50K$75K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20183,275$44K
20192,256$75K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 25% 1,565 1,157 $29K
81162 16% 35 33 $19K
81321 12% 148 141 $14K
81298 9.1% 145 139 $11K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 8.5% 1,154 766 $10K
81292 5.8% 42 40 $7K
81295 5.4% 147 141 $6K
81317 3.2% 74 69 $4K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 3.1% 228 211 $4K
81405 2.5% 249 155 $3K
81404 1.9% 230 138 $2K
81406 1.8% 250 154 $2K
13 more codes
81323 1.2% 39 $1K
81300 <1% 39 $1K
81297 <1% 26 $1K
81319 <1% 39 $976.80
81294 <1% 39 $971.52
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 233 $871.52
81403 <1% 163 $685.26
81242 <1% 139 $602.09
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 95 $94.40
81408 0% 235 $0.00
81479 Unlisted molecular pathology procedure 0% 49 $0.00
81201 0% 142 $0.00
81203 0% 26 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSTEWART, TAYLOR (PRESIDENT)
Same official

Other billing entities under STEWART, TAYLOR

Full network →
ProviderLocationPaid
Moment to Moment LLPColumbus, OH$74K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.